Integrated pharmacokinetic-pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections

about

Integrated pharmacokinetic-pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections

Item

http://www.wikidata.org/entity/Q57491074

description

im Jahr 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Integrated pharmacokinetic-pha ...... rapy in bloodstream infections

@en

Integrated pharmacokinetic-pha ...... rapy in bloodstream infections

@nl

type

Item

label

Integrated pharmacokinetic-pha ...... rapy in bloodstream infections

@en

Integrated pharmacokinetic-pha ...... rapy in bloodstream infections

@nl

prefLabel

Integrated pharmacokinetic-pha ...... rapy in bloodstream infections

@en

Integrated pharmacokinetic-pha ...... rapy in bloodstream infections

@nl

P1476

Integrated pharmacokinetic-pha ...... rapy in bloodstream infections

@en

P2093

Andrea L Kwa

http://www.w3.org/2001/XMLSchema#string

Gang Quan Poh

http://www.w3.org/2001/XMLSchema#string

Pui Lai Rachel Ee

http://www.w3.org/2001/XMLSchema#string

Reyna Wang

http://www.w3.org/2001/XMLSchema#string

Thean-Yen Tan

http://www.w3.org/2001/XMLSchema#string

Thuan-Tong Tan

http://www.w3.org/2001/XMLSchema#string

Tse-Hsien Koh

http://www.w3.org/2001/XMLSchema#string

Tze-Peng Lim

http://www.w3.org/2001/XMLSchema#string

Winnie Lee

http://www.w3.org/2001/XMLSchema#string

Yiying Cai

http://www.w3.org/2001/XMLSchema#string

P2860

Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.

Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Introduction: the challenge of multiresistance.

The role of carbapenems in initial therapy for serious Gram-negative infections.

Pharmacokinetic and pharmacodynamic properties of meropenem.

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.

P304

1591-1596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IDR.S168191

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jocelyn Qi-Min Teo

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30310294

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

infectious disease

P932

6166767

http://www.w3.org/2001/XMLSchema#string